A method for preparing a key intermediate of zolmitriptan
By simplifying the synthesis process of zomitriptan intermediate, L-phenylalanol is used to perform ring-closing, iodide and amination reactions, the problems of cumbersome synthesis and environmental pollution in the prior art are solved, and low-cost Environmentally friendly industrial production.
Patent Information
- Application Number
- CN202311512323.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-11-14
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2043-11-14
AI Technical Summary
The synthesis process of the existing key zomitriptan intermediate (S)-4-(4-aminobenzyl)-2-oxazolidinone is cumbersome, resulting in a large amount of waste solids, is unfriendly in the environment, and the use of catalysts is safe. Hidden dangers lead to high overall costs.
Using L-phenylalanol as raw material, the three-step reactions are carried out: closure, iodo and amination reaction to produce (S)-4-(4-aminobenzyl)-2-oxazolidinone, with concise steps. The operation is stable, the product is easy to separate, reducing the amount of waste and raw material costs.
The simplified synthesis route has been achieved, reduced production costs, improved the environmental protection and safety of the process, and provided a new way suitable for industrial production.
Smart Images

Figure BDA0004547783630000021 
Figure FHA0000007264830000011
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of organic synthesis, and in particular to a method for preparing a key intermediate of zolmitriptan. Background Art
[0002] Zolmitriptan, chemically known as (S)-4-[3-[2-(dimethylamino)ethyl]-1H-indole-5-methyl]-2-oxazolidinone, is an anti-migraine drug developed by the German Glaxo-Wellcome Company. It is a highly selective 5-hydroxytryptamine (5-TH1B and 5-TH1D) receptor agonist that relieves migraine attacks by stimulating 5-HTIB / ID receptors on intracranial blood vessels (including arteriovenous anastomoses) and sympathetic nerves of the trigeminal nervous system, contracting blood vessels and inhibiting the release of neuropeptides. It has been listed in the UK, the US and other countries, and has a good market prospect.
[0003] (S)-4-(4-aminobenzyl)-2-oxazolidinone is an important intermediate in the synthesis of zolmitriptan. At present, (S)-4-(4-aminobenzyl)-2-oxazolidinone is mainly prepared by using (S)-4-(4-nitrobenzyl)-2-oxazolidinone as a raw material and reducing it with ferric chloride hexahydrate, activated carbon and hydrazine hydrate. However, the above method has the following disadvantages:
[0004] (1) Iron sludge is produced during the reaction, which is difficult to centrifuge and produces a large amount of waste solids, which is not environmentally friendly;
[0005] (2) In order to maintain the high activity of the catalyst, a considerable excess of hydrazine hydrate must be used to compensate for the loss caused by the self-decomposition of hydrazine hydrate. In addition, activated carbon contaminated with hydrazine hydrate is also at risk of catching fire if left in the air for a long time, posing a great safety hazard.
[0006] In summary, the synthesis of (S)-4-(4-aminobenzyl)-2-oxazolidinone in the prior art is complicated, has a large amount of three wastes, and has a high overall cost. Therefore, it is particularly important to develop a synthetic route that is concise, has a simple and reliable process, is low in cost, and is suitable for industrial production. Summary of the invention
[0007] The object of the present invention is to provide a method for preparing (S)-4-(4-aminobenzyl)-2-oxazolidinone with simple steps, simple and reliable process and easy industrial production. The process is divided into three steps. In the first step, L-phenylalaninol is ring-closed under the action of alkali and carbonylating agent to generate (S)-4-benzyl-2-oxazolidinone; in the second step, (S)-4-benzyl-2-oxazolidinone, iodine, sodium iodide and periodic acid undergo iodination reaction to generate (S)-4-(4-iodobenzyl)-2-oxazolidinone; in the third step, (S)-4-(4-iodobenzyl)-2-oxazolidinone, ammonia water, copper salt, alkali and catalyst are heated in an organic solvent to obtain (S)-4-(4-aminobenzyl)-1,3-oxazolidin-2-one. The technical scheme of the present invention is simple and stable to operate, the products in each step are easy to separate, the yield is high, and it is environmentally friendly, and provides a new synthetic route for (S)-4-(4-aminobenzyl)-2-oxazolidinone.
[0008] The preparation method of a key intermediate of zolmitriptan described in the present invention has the following synthesis route:
[0009]
[0010] The first step is a ring-closing reaction: L-phenylalaninol is subjected to a ring-closing reaction under the action of a base and a carbonylating agent to generate (S)-4-benzyl-2-oxazolidinone.
[0011] Furthermore, in the above technical solution, the molar ratio of L-phenylalaninol, base and carbonylation agent is 1:0.01-0.05:1-3.
[0012] Furthermore, in the above technical solution, the base is selected from potassium carbonate, sodium carbonate, cesium carbonate and the like.
[0013] Furthermore, in the above technical solution, the carbonylating agent is selected from diethyl carbonate, dimethyl carbonate and N,N-carbonyldiimidazole.
[0014] Furthermore, in the above technical solution, the reaction temperature is controlled at 110-130°C.
[0015] The second step is iodination reaction: (S)-4-benzyl-2-oxazolidinone, iodine, sodium iodide and periodic acid are subjected to iodination reaction to generate (S)-4-(4-iodobenzyl)-2-oxazolidinone.
[0016] Furthermore, in the above technical solution, the molar ratio of (S)-4-benzyl-2-oxazolidinone, iodine, sodium iodide and periodic acid is 1:0.4-0.5:0.1-0.3:0.02-0.04.
[0017] The third step is amination reaction: (S)-4-(4-iodobenzyl)-2-oxazolidinone, ammonia water, copper salt, base and catalyst are heated in an organic solvent to obtain (S)-4-(4-aminobenzyl)-1,3-oxazolidin-2-one.
[0018] Furthermore, in the above technical solution, the molar ratio of (S)-4-(4-iodobenzyl)-2-oxazolidinone, aqueous ammonia, copper salt, base and catalyst is 1:3-5:0.1-0.3:2-3:0.2-0.4.
[0019] Furthermore, in the above technical solution, the catalyst is selected from L-hydroxyproline, sodium vitamin C, D-glucosamine hydrochloride, L-valine, etc.
[0020] Furthermore, in the above technical solution, the base is selected from potassium phosphate, cesium carbonate, potassium carbonate, potassium hydroxide, sodium hydroxide and harmaline.
[0021] Furthermore, in the above technical solution, the copper salt is selected from cuprous bromide, cuprous iodide, cupric acetylacetonate, cuprous oxide and copper (II) trifluoromethanesulfonate, etc.
[0022] Furthermore, in the above technical solution, the organic solvent is selected from ethanol, dimethyl sulfoxide, N,N-dimethylformamide, methanol, dioxane, acetone and acetonitrile.
[0023] Compared with the prior art, the present invention has the following significant advantages:
[0024] 1) The present invention avoids the disadvantages of long synthetic route and complicated reaction steps, and the cost is lower;
[0025] 2) The present invention has a short process, greatly reduces the amount of three wastes, and the entire preparation process is more environmentally friendly;
[0026] 3) The overall production cost is much lower than that of currently known processes, and the synthetic process is more competitive in the market.
[0027] Beneficial effects of the present invention
[0028] The core point of the present invention is to use L-phenylalaninol as a raw material, shorten the synthesis route, reduce the amount of three wastes, and reduce the cost of raw materials. The technical scheme of the present invention is simple and stable to operate, the products of each step are easy to separate, the yield is high, and it is environmentally friendly, providing a new synthesis route for (S)-4-(4-aminobenzyl)-2-oxazolidinone. DETAILED DESCRIPTION
[0029] The present invention will be further described below in conjunction with specific embodiments. These embodiments should be understood to be only used to illustrate the present invention and not to limit the scope of protection of the present invention. After reading the content of the present invention, those skilled in the art may make various changes or modifications to the present invention, and these equivalent changes and modifications also fall within the scope defined by the claims of the present invention.
[0030] Example 1
[0031] Anhydrous potassium carbonate (19.34 g, 0.14 mol) was added to a solution of L-phenylalaninol (648.69 g, 4.29 mol) and diethyl carbonate (1013.56 g, 8.58 mol), and the reaction was stirred at 120-130°C for 3 hours. The spot plate confirmed that the raw material spot disappeared, 1N dilute hydrochloric acid was added to quench the reaction, and ethyl acetate was extracted and dried to obtain 746.5 g of a white solid (yield 98.2%). The structure was confirmed to be (S)-4-benzyl-2-oxazolidinone by nuclear magnetic resonance. 1 H NMR (400MHz, CDCl3): 7.41-7.24(m,3H), 7.24-7.14(m,2H), 6.04(s,1H), 4.51-4.37(m,1H), 4.21-4.03(m,2H), 2.97-2.79(m,1H).
[0032] Example 2
[0033] Anhydrous sodium carbonate (22.26 g, 0.21 mol) was added to a solution of L-phenylalaninol (648.69 g, 4.29 mol) and dimethyl carbonate (1159.33 g, 12.87 mol), and the reaction was stirred at 120-130° C. for 3 hours. The spot plate confirmed that the raw material spot disappeared, 1N dilute hydrochloric acid was added to quench the reaction, and ethyl acetate was extracted and dried to obtain 701.65 g of a white solid (yield 92.3%).
[0034] Example 3
[0035] Anhydrous cesium carbonate (0.43 kg, 1.32 mol) was added to a solution of L-phenylalaninol (10 kg, 66.13 mol) and carbonyldiimidazole (10.72 kg, 66.13 mol), and the reaction was stirred at 110-120° C. for 3 hours. The plate was used to confirm that the raw material spot disappeared, and 1N dilute hydrochloric acid was added to quench the reaction. The mixture was extracted with ethyl acetate and dried to obtain 10.50 kg of a white solid (yield 89.6%).
[0036] Example 4
[0037] Iodine (25.38 g, 100 mmol) and sodium iodide (7.49 g, 50 mmol) were added to a solution of (S)-4-benzyl-2-oxazolidinone (44.3 g, 250 mmol) in glacial acetic acid (250 mL) and concentrated sulfuric acid (31 mL), and the reaction was stirred at 70°C for 18 hours. Then, periodic acid (2.28 g, 10 mmol) was added to the reaction system, and the reaction was continued to stir at 70°C for 30 minutes. Water was added to quench the reaction, and the mixture was extracted with dichloromethane, dried, and spin-dried to obtain 54.91 g of a yellow solid (S)-4-(4-iodobenzyl)-2-oxazolidinone (yield 72.5%).
[0038] Example 5
[0039] Iodine (31.73 g, 125 mmol) and sodium iodide (3.75 g, 25 mmol) were added to a solution of (S)-4-benzyl-2-oxazolidinone (44.3 g, 250 mmol) in glacial acetic acid (250 mL) and concentrated sulfuric acid (31 mL), and the reaction was stirred at 70°C for 18 hours. Then, periodic acid (1.14 g, 5 mmol) was added to the reaction system, and the reaction was continued to stir at 70°C for 30 minutes. Water was added to quench the reaction, and the mixture was extracted with dichloromethane, dried, and spin-dried to obtain 51.66 g of a yellow solid (S)-4-(4-iodobenzyl)-2-oxazolidinone (yield 68.2%).
[0040] Example 6
[0041] Iodine (7.11 kg, 28 mol) and sodium iodide (0.84 kg, 5.6 mol) were added to a solution of (S)-4-benzyl-2-oxazolidinone (10 kg, 56 mol) in glacial acetic acid (50 L) and concentrated sulfuric acid (6.25 L), and the reaction was stirred at 70°C for 18 hours. Then, periodic acid (0.38 kg, 1.68 mol) was added to the reaction system, and the reaction was continued to stir at 70°C for 30 minutes. Water was added to quench the reaction, and the mixture was extracted with dichloromethane, dried, and spin-dried to obtain 11.83 kg of yellow solid (S)-4-(4-iodobenzyl)-2-oxazolidinone (yield 69.7%).
[0042] Example 7
[0043] Add ammonia water (125ml) to a dimethyl sulfoxide (500mL) solution of cuprous bromide (9.47g, 66.01mmol), potassium phosphate (210.18g, 990.15mmol) and (S)-4-(4-iodobenzyl)-2-oxazolidinone (100g, 330.05mmol), L-hydroxyproline (17.31g, 132.02mmol), stir at 50℃ for 24 hours, pour the reaction solution into ice water, extract with dichloromethane, wash the organic phase with dilute hydrochloric acid, adjust the pH of the aqueous phase to 9-10 with sodium hydroxide aqueous solution, extract twice with methyl tert-butyl ether, dry, and spin dry to obtain (S)-4-(4-aminobenzyl)-1,3-oxazolidin-2-one (55.51g, yield 87.5%). HNMR detection shows that the structure is correct: 1 H NMR (400MHz, CDCl3): 6.88(2H,d),6.56(2H,d),5.81(1H,m),4.09(1H,m),3.92(2H,m),3.69(2H,brs),3.05(1H,d),2.49(1H,d);
[0044] Example 8
[0045] Ammonia water (125 ml) was added to a solution of cuprous iodide (12.57 g, 66.01 mmol), cesium carbonate (215.07 g, 660.10 mmol) and (S)-4-(4-iodobenzyl)-2-oxazolidinone (100 g, 330.05 mmol) / dioxane (500 ml), L-valine (15.47 g, 132.02 mmol), stirred at 50°C for 24 hours, the reaction solution was poured into ice water, extracted with dichloromethane, the organic phase was washed with dilute hydrochloric acid, the aqueous phase was adjusted to pH = 9-10 with sodium hydroxide aqueous solution, extracted twice with methyl tert-butyl ether, dried, and spin-dried to obtain (S)-4-(4-aminobenzyl)-1,3-oxazolidin-2-one (52.27 g, yield 82.4%). HNMR detection showed that the structure was correct.
[0046] Example 9
[0047] Ammonia water (12.5L) was added to copper (II) trifluoromethanesulfonate (6.60mmol), sodium hydroxide (2.64kg, 66.02mol) and (S)-4-(4-iodobenzyl)-2-oxazolidinone (10kg, 33.01mol) / N,N-dimethylformamide (50L) solution, L-valine (0.77kg, 6.60mol), stirred at 50℃ for 24 hours, the reaction solution was poured into ice water, extracted with dichloromethane, the organic phase was washed with dilute hydrochloric acid, the aqueous phase was adjusted to pH = 9-10 with sodium hydroxide aqueous solution, extracted twice with methyl tert-butyl ether, dried, and spin-dried to obtain (S)-4-(4-aminobenzyl)-1,3-oxazolidin-2-one (5.15kg, yield 81.2%). HNMR detection showed that the structure was correct.
[0048] The above shows and describes the basic principles and main features of the present invention and the advantages of the present invention. It should be understood by those skilled in the art that the present invention is not limited by the above embodiments, and the above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, and these changes and improvements all fall within the scope of the present invention to be protected.
Claims
1. A method for preparing a key intermediate of zolmitriptan, characterized in that: The steps include: The first step is to close the ring of L-phenylalaninol under the action of a base and a carbonylating agent to generate (S)-4-benzyl-2-oxazolidinone; the base is selected from potassium carbonate, sodium carbonate or cesium carbonate; the carbonylating agent is selected from diethyl carbonate, dimethyl carbonate or N,N-carbonyldiimidazole; the reaction temperature is controlled at 110-130°C; the molar ratio of L-phenylalaninol, base and carbonylating agent is 1:0.01-0.05:1-3; In the second step, (S)-4-benzyl-2-oxazolidinone, iodine, sodium iodide and periodic acid are subjected to iodination reaction to generate (S)-4-(4-iodobenzyl)-2-oxazolidinone; In the third step, (S)-4-(4-iodobenzyl)-2-oxazolidinone, ammonia water, a copper salt, a base and a catalyst are heated in an organic solvent to react to obtain (S)-4-(4-aminobenzyl)-1,3-oxazolidin-2-one; the copper salt is selected from cuprous bromide, cuprous iodide, cupric acetylacetonate, cuprous oxide or copper trifluoromethanesulfonate; and the catalyst is selected from L-hydroxyproline or L-valine.
2. The method for preparing the key intermediate of zolmitriptan according to claim 1, characterized in that: In the second step, the molar ratio of (S)-4-benzyl-2-oxazolidinone, iodine, sodium iodide and periodic acid is 1:0.4-0.5:0.1-0.3:0.02-0.
04.
3. The method for preparing the key intermediate of zolmitriptan according to claim 1, characterized in that: In the third step, the base is selected from potassium phosphate, cesium carbonate, potassium carbonate, potassium hydroxide, sodium hydroxide or harmaline.
4. The method for preparing the key intermediate of zolmitriptan according to claim 1, characterized in that: In the third step, the organic solvent is selected from ethanol, dimethyl sulfoxide, N,N-dimethylformamide, methanol, dioxane, acetone or acetonitrile.
5. The method for preparing the key intermediate of zolmitriptan according to claim 1, characterized in that: In the third step, the molar ratio of (S)-4-(4-iodobenzyl)-2-oxazolidinone, aqueous ammonia, copper salt, base and catalyst is 1:3-5:0.1-0.3:2-3:0.2-0.4.
